Recombinant antivenoms based on mixtures of human antibodies against D. jamesoni toxins

Urska Pus, Robert Harrison, Mikael Rørdam Andersen, Nicholas Casewell, Andreas Hougaard Laustsen

    Research output: Contribution to conferencePosterResearchpeer-review

    75 Downloads (Pure)

    Abstract

    Each year, more than 5 million people worldwide are affected by a snakebite, resulting in 150,000 deaths, and 400,000 amputations. The current medical treatment against envenoming is based on the administration of an animal-derived antiserum, containing antibodies against snake venom toxins. Due to the heterologous and immunogenic nature of antivenom, patients in up to 80% of the cases experience serum sickness and anaphylaxis, which in some cases leads to death.
    Original languageEnglish
    Publication date2016
    Number of pages1
    Publication statusPublished - 2016
    EventSymposium for Biological and Life Science Students (SymBLS) 2016 - Cambridge, United Kingdom
    Duration: 25 Nov 201625 Nov 2016

    Conference

    ConferenceSymposium for Biological and Life Science Students (SymBLS) 2016
    CountryUnited Kingdom
    CityCambridge
    Period25/11/201625/11/2016

    Fingerprint Dive into the research topics of 'Recombinant antivenoms based on mixtures of human antibodies against <i>D. jamesoni </i>toxins'. Together they form a unique fingerprint.

    Cite this